WHOLE-GENOME NEWBORN SCREENING: LEGAL AND REGULATORY FRAMEWORK IN RUSSIA

1. INTRODUCTION

Whole-genome newborn screening involves analysing an infant's complete genetic material to identify inherited disorders, disease-associated mutations, genetic predispositions and other clinically significant genomic variations. Unlike conventional newborn screening, which generally examines a limited number of conditions through biochemical or molecular tests, whole-genome sequencing can potentially identify thousands of genetic variations.

In Russia, whole-genome newborn screening raises significant legal questions concerning parental consent, children's rights, genetic privacy, medical confidentiality, discrimination, storage of genomic information and the permissible use of genetic data for research.

Russia does not currently have a standalone federal law specifically establishing universal whole-genome sequencing of all newborns. Instead, the relevant activities are governed by legislation concerning healthcare, genetic research, medical examinations, personal information and pharmaceutical and medical-device regulation.

2. PRINCIPAL LEGAL FRAMEWORK

A. FEDERAL LAW NO. 323-FZ ON THE FUNDAMENTALS OF HEALTH PROTECTION

Federal Law No. 323-FZ establishes the general framework for medical examinations, diagnosis, treatment and patient rights.

Its relevant provisions include:

Article 13: Medical confidentiality.

Article 20: Informed voluntary consent and refusal of medical intervention.

Article 22: Patients' rights to receive information concerning their health.

Article 54: Rights of minors in healthcare.

For newborn genomic screening, parents or other legally authorised representatives generally participate in consent decisions in accordance with applicable rules governing medical intervention involving minors.

The healthcare provider must explain the purpose, benefits, limitations and potential consequences of genetic testing.

B. FEDERAL LAW NO. 152-FZ ON PERSONAL DATA

This legislation is particularly important because genomic information can identify individuals and reveal sensitive information about inherited diseases and family relationships.

Article 10 establishes special protection for specified categories of personal data, including health-related information.

Relevant compliance requirements include:

Establishing a lawful basis for processing genomic information.

Obtaining legally required consent where applicable.

Limiting data collection to legitimate purposes.

Protecting genetic information against unauthorised access.

Establishing appropriate retention arrangements.

Regulating disclosure to third parties.

Complying with applicable international data-transfer requirements.

C. FEDERAL LAW NO. 242-FZ OF 2014

This legislation introduced important amendments concerning personal-data localisation.

Where Russian citizens' personal data are collected through internet-based services, applicable requirements concerning recording, systematisation, accumulation, storage and other processing operations within Russia must be considered.

It is relevant to genomic screening platforms that use international cloud infrastructure.

D. FEDERAL LAW NO. 86-FZ ON STATE REGULATION IN THE FIELD OF GENETIC ENGINEERING ACTIVITIES

This legislation regulates specified genetic-engineering activities and associated biosafety requirements.

Its application to whole-genome newborn screening is limited: ordinary DNA sequencing and genetic diagnosis do not automatically constitute genetic-engineering activities.

E. FEDERAL LAW NO. 157-FZ ON IMMUNOPROPHYLAXIS OF INFECTIOUS DISEASES

This law is relevant only where newborn screening programmes intersect with vaccination and infectious-disease prevention. It does not independently establish genomic newborn-screening requirements.

3. NEWBORN SCREENING AND NATIONAL HEALTHCARE PROGRAMMES

Russia operates a national newborn screening programme intended to identify serious inherited and congenital conditions at an early stage.

The programme was expanded from 1 January 2023 to cover 36 hereditary and congenital diseases, including conditions requiring early diagnosis and intervention.

The expanded programme is based on governmental and Ministry of Health regulatory measures, including Government Resolution No. 912 of 18 June 2021 and Ministry of Health Order No. 274n of 21 April 2022.

It is important to distinguish this established expanded newborn screening programme from universal whole-genome sequencing.

Conventional screening generally uses targeted biochemical and molecular methods. Whole-genome screening would generate substantially broader information, including findings unrelated to immediate childhood medical needs.

Consequently, universal whole-genome screening requires additional consideration of consent, clinical validity, data governance and ethical safeguards.

4. PARENTAL CONSENT AND CHILDREN'S RIGHTS

Newborns cannot independently provide informed consent. Therefore, parents or legally authorised representatives generally exercise relevant consent responsibilities under Russian healthcare law.

Consent procedures should address:

The purpose of genomic sequencing.

Diseases and genetic conditions being investigated.

Possible incidental findings.

Limitations of genetic predictions.

The possibility of uncertain genetic variants.

Whether results may reveal inherited conditions in parents.

Data storage and future research use.

Disclosure of clinically significant findings.

Article 20 of Federal Law No. 323-FZ is particularly relevant to consent for medical intervention.

Parental authorisation should not be interpreted as unlimited permission to use a child's genomic information for unrelated commercial or research purposes.

5. GENOMIC DATA PRIVACY AND BIOBANK GOVERNANCE

Whole-genome sequencing generates information that may remain relevant throughout an individual's lifetime.

Important legal considerations include:

A. MEDICAL CONFIDENTIALITY

Genetic results obtained through healthcare activities are subject to applicable medical-confidentiality requirements under Article 13 of Federal Law No. 323-FZ.

B. DATA SECURITY

Healthcare institutions should maintain encryption, controlled access, audit trails and secure genomic databases.

C. BIOBANK STORAGE

Where biological samples are retained for future research, institutions should establish appropriate consent, storage, access and destruction procedures under applicable legislation and ethical requirements.

D. INTERNATIONAL DATA SHARING

Genomic information transferred to foreign research institutions must comply with Russian personal-data legislation, including applicable cross-border transfer requirements.

E. SECONDARY USE

Using newborn genomic information for unrelated research, commercial analysis or population-genetics projects requires an appropriate legal basis and compliance with relevant consent and research-governance requirements.

6. ETHICAL AND REGULATORY CHALLENGES

A. INCIDENTAL GENETIC FINDINGS

Whole-genome sequencing may identify adult-onset diseases, carrier status or genetic risks that do not affect the newborn's immediate healthcare.

A responsible programme should establish clear policies on which findings are clinically actionable and appropriate to disclose during childhood.

B. GENETIC DISCRIMINATION

Genomic information may potentially be misused by employers, insurers or other third parties. Healthcare institutions must protect confidential information and prevent unlawful disclosure.

C. PSYCHOLOGICAL AND FAMILY CONSEQUENCES

Genetic results may reveal unexpected biological relationships or hereditary conditions affecting several family members.

D. SCIENTIFIC ACCURACY

Genetic variants must be interpreted using scientifically validated methods. A detected variant does not automatically establish that a child will develop a particular disease.

E. EQUITABLE ACCESS

Public screening programmes should avoid unjustified differences in access based on geographical location, financial circumstances or social status.

7. RELEVANT CASE LAWS AND JUDICIAL AUTHORITIES

There is no established body of Russian judicial decisions specifically addressing universal whole-genome newborn screening. The following European Court of Human Rights decisions provide analogous legal principles concerning genetic testing, medical confidentiality, reproductive autonomy and children's rights.

1. COSTA AND PAVAN v. ITALY (2012)

The European Court of Human Rights examined access to preimplantation genetic diagnosis by prospective parents carrying a hereditary genetic disorder.

The Court considered reproductive autonomy and access to genetic testing.

Relevance: Analogous authority concerning genetic diagnosis and reproductive decision-making.

2. S. AND MARPER v. THE UNITED KINGDOM (2008)

The Grand Chamber examined the indefinite retention of fingerprints and DNA profiles of individuals who had not been convicted of criminal offences.

The Court found that blanket and indiscriminate retention violated Article 8 of the European Convention.

Relevance: Important analogous authority concerning genetic-data retention, privacy and proportionality. Although it concerned forensic DNA databases rather than medical newborn screening, its privacy principles are significant.

3. GASKIN v. THE UNITED KINGDOM (1989)

The Court examined access to confidential records concerning an individual's childhood and personal history.

It recognised the importance of access to personal information while balancing confidentiality interests.

Relevance: Analogous authority concerning access to childhood medical and personal records.

4. Z v. FINLAND (1997)

The Court considered the disclosure of confidential medical information and the protection of private life.

It emphasised that confidentiality is essential to maintaining public confidence in healthcare services.

Relevance: Analogous authority concerning the confidentiality of newborn genomic and hereditary medical information.

5. I. v. FINLAND (2008)

The Court examined inadequate safeguards governing access to a patient's confidential medical records.

It stressed the need for effective security measures protecting sensitive health information.

Relevance: Analogous authority concerning cybersecurity and restricted access to genomic databases.

6. EVANS v. THE UNITED KINGDOM (2007)

The Court examined consent and competing rights concerning embryos created through assisted reproductive technologies.

Relevance: Limited analogous authority concerning reproductive autonomy, consent and the ethical management of genetic information. It does not directly establish rules for newborn screening.

These judgments are comparative authorities rather than direct Russian judicial precedents.

8. LIABILITY AND REGULATORY ENFORCEMENT

Healthcare providers, laboratories and research institutions may incur liability for violations involving newborn genomic screening.

Potential violations include:

Conducting medical interventions without legally required consent.

Unauthorised disclosure of genetic information.

Improper retention of genomic data.

Negligent genetic interpretation.

Failure to communicate clinically significant findings appropriately.

Unlawful secondary use of biological samples.

Inadequate cybersecurity protection.

Misrepresentation of screening accuracy.

Depending on the circumstances, liability may arise under civil, administrative or criminal legislation.

Relevant enforcement provisions may include Article 13.11 of the Code of Administrative Offences concerning personal-data processing violations and Article 137 of the Criminal Code concerning unlawful violations of privacy.

9. PRACTICAL COMPLIANCE REQUIREMENTS

Russian hospitals, genetic laboratories and newborn-screening research institutions should implement the following safeguards:

Distinguish targeted newborn screening from whole-genome sequencing.

Establish a lawful basis for genetic-data processing.

Obtain appropriate parental consent.

Provide clear explanations of clinical benefits and limitations.

Use validated sequencing and variant-interpretation methods.

Establish policies for incidental findings.

Maintain secure genomic databases.

Restrict access to authorised medical professionals.

Establish transparent biological-sample retention policies.

Regulate secondary research use.

Maintain procedures for communicating clinically significant findings.

Comply with applicable Russian data-localisation and international-transfer requirements.

10. CONCLUSION

Whole-genome newborn screening in Russia operates within a broader framework of healthcare regulation, medical confidentiality, personal-data protection and genetic research governance. Federal Laws Nos. 323-FZ, 152-FZ and 86-FZ, together with the expanded national newborn-screening programme introduced in 2023, provide relevant legal foundations.

However, Russia's established programme covering 36 hereditary and congenital diseases should not be confused with universal whole-genome sequencing. The latter raises additional questions concerning lifelong genomic privacy, parental consent, incidental findings, secondary research use and genetic discrimination.

The judgments in S. and Marper v. United Kingdom, Z v. Finland and I. v. Finland provide particularly useful analogous principles concerning genetic privacy, data retention and medical confidentiality. Ultimately, a responsible whole-genome newborn-screening framework requires scientifically validated testing, informed parental participation, strict genomic-data security, clinically appropriate disclosure and protection of the child's future autonomy.